Endometrial
12
3
3
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
2 terminated out of 12 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (12)
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Asymptomatic Women With Thick Endometrium: Hysteroscopic and Histopathological Report
A Study of SGN-MesoC2 in Advanced Solid Tumors
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Impact of Prior Identification and Education of Patients Requiring a Digestive Stoma for Fecal Diversion
EFFECTIVENESS OF PREOPERATIVE VAGINAL CLEANING IN REDUCING POST CAESAREAN INFECTIOUS MORBIDITY
Effect of Tranexamic Acid and Calcium Dobesilate for Bleeding of Endometrial Origin
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Endometrial Gene Expression in Different Protocols of Endometrial Preparation for Embryo Transfer'